MAP1LC3A Gene

MAP1LC3A Gene[@mizushima2002]

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP1LC3A Gene</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>MAP1LC3A/Autophagy Status</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Impaired autophagy, TDP-43 aggregates colocalize with LC3[@kawabata2021]</td>
</tr>
<tr>
<td class="label">Prion Disease</td>
<td>Autophagy required for prion protein clearance[@nixon2005]</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy</td>
<td>α-synuclein aggregates trigger autophagy dysfunction[@xilouri2016]</td>
</tr>
<tr>
<td class="label">Vitamin D Deficiency</td>
<td>Reduced LC3 expression in substantia nigra</td>
</tr>
<tr>
<td class="label">Dementia with Lewy Bodies</td>
<td>Impaired autophagic flux, LC3 accumulation</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>Tau pathology impairs autophagy</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>TDP-43 and autophagy dysfunction</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Alzheimer's Dise

MAP1LC3A Gene[@mizushima2002]

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP1LC3A Gene</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>MAP1LC3A/Autophagy Status</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Impaired autophagy, TDP-43 aggregates colocalize with LC3[@kawabata2021]</td>
</tr>
<tr>
<td class="label">Prion Disease</td>
<td>Autophagy required for prion protein clearance[@nixon2005]</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy</td>
<td>α-synuclein aggregates trigger autophagy dysfunction[@xilouri2016]</td>
</tr>
<tr>
<td class="label">Vitamin D Deficiency</td>
<td>Reduced LC3 expression in substantia nigra</td>
</tr>
<tr>
<td class="label">Dementia with Lewy Bodies</td>
<td>Impaired autophagic flux, LC3 accumulation</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>Tau pathology impairs autophagy</td>
</tr>
<tr>
<td class="label">Corticobasal Degeneration</td>
<td>TDP-43 and autophagy dysfunction</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Lithium</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Trehalose</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Metformin</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">[p62/SQSTM1](/genes/sqstm1)</td>
<td>LC3-binding cargo receptor</td>
</tr>
<tr>
<td class="label">[ATG5](/genes/atg5)</td>
<td>Autophagy conjugation system</td>
</tr>
<tr>
<td class="label">[ATG7](/genes/atg7)</td>
<td>E1-like activating enzyme</td>
</tr>
<tr>
<td class="label">[ATG3](/genes/atg3)</td>
<td>E2-like conjugating enzyme</td>
</tr>
<tr>
<td class="label">[ATG4B](/genes/atg4b)</td>
<td>Protease for processing</td>
</tr>
<tr>
<td class="label">[GABARAP](/proteins/gabarap-protein)</td>
<td>Related family member</td>
</tr>
<tr>
<td class="label">[LAMP1/LAMP2](/genes/lamp1)</td>
<td>Lysosomal membrane proteins</td>
</tr>
<tr>
<td class="label">[NBR1](/genes/nbr1)</td>
<td>Alternative cargo receptor</td>
</tr>
<tr>
<td class="label">[optineurin](/genes/optn)</td>
<td>Mitophagy receptor</td>
</tr>
<tr>
<td class="label">[TBK1](/genes/tbk1)</td>
<td>Kinase for receptor phosphorylation</td>
</tr>
<tr>
<td class="label">[ULK1](/genes/ulk1)</td>
<td>Kinase complex component</td>
</tr>
<tr>
<td class="label">[Beclin 1](/genes/becn1)</td>
<td>PI3K complex component</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction with MAP1LC3A</td>
</tr>
<tr>
<td class="label">[SNCA](/genes/snca)</td>
<td>LC3-mediated aggrephagy clears α-synuclein aggregates</td>
</tr>
<tr>
<td class="label">[PINK1](/genes/pink1)</td>
<td>Recruits LC3 to damaged mitochondria for mitophagy</td>
</tr>
<tr>
<td class="label">[Parkin](/genes/parkin)</td>
<td>Mediates ubiquitination for mitophagy receptor recruitment</td>
</tr>
<tr>
<td class="label">[SOD1](/genes/sod1)</td>
<td>Mutant SOD1 requires LC3 autophagy for clearance</td>
</tr>
<tr>
<td class="label">[TDP-43](/genes/tardbp)</td>
<td>ALS-associated aggregates cleared by LC3</td>
</tr>
<tr>
<td class="label">[LRRK2](/genes/lrrk2)</td>
<td>Regulates autophagy through kinase activity</td>
</tr>
<tr>
<td class="label">[GBA](/genes/gba)</td>
<td>Glucocerebrosidase affects autophagic-lysosomal function</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">357 edges</a></td>
</tr>
</table>

Gene: MAP1LC3A | Protein: MAP1LC3A (Microtubule-Associated Protein 1 Light Chain 3 Alpha) | Aliases: ATG8, LC3, MAP1A/MAP1B, MAP1L3A

Introduction

The MAP1LC3A gene encodes MAP1LC3A (Microtubule-Associated Protein 1 Light Chain 3 Alpha), a critical protein in the autophagy pathway. Formerly known as LC3, this protein is a key structural component of the autophagosome, the double-membraned vesicle that engulfs cellular components for degradation and recycling [1]. MAP1LC3A is essential for autophagosome formation, cargo recruitment, and membrane fusion events during autophagy.

The MAP1LC3A protein is the mammalian ortholog of yeast Atg8 and belongs to the MAP1LC3 family, which includes MAP1LC3B, MAP1LC3B2, and MAP1LC3C. Among these, MAP1LC3A and MAP1LC3B are the most widely studied and functionally significant isoforms. The discovery of LC3 as a mammalian homolog of Atg8 marked a pivotal moment in understanding the molecular mechanisms of autophagy in higher eukaryotes.

Gene Structure and Expression

Genomic Location

The MAP1LC3A gene is located on chromosome 20q11.22 in humans. It spans approximately 12 kb and consists of 7 exons encoding a 121-amino acid protein. The gene is situated in a region of the genome that shows evolutionary conservation across mammals, reflecting its fundamental cellular function.

The promoter region of MAP1LC3A contains several regulatory elements:

• TATA box: Found approximately 25bp upstream of the transcription start site
• GC-rich regions: Multiple Sp1 binding sites
• ARE (antioxidant response element): Allows Nrf2-mediated regulation
• CRE (cAMP response element): Enables cAMP-dependent regulation

Alternative Splicing

MAP1LC3A undergoes alternative splicing, producing multiple transcript variants:

• Variant 1 (canonical): Full-length protein encoding the functional LC3A
• Variant 2: Lacks exon 3, producing a shorter isoform with potentially altered function
• Variant 3: Uses an alternative start site, generating an N-terminally truncated protein
• Variant 4: Includes alternative exon skipping, producing distinct protein isoforms

Tissue Distribution

MAP1LC3A is ubiquitously expressed across tissues, with highest expression in:

• Brain: Particularly high in neurons of the cortex, hippocampus, and cerebellum
• Liver: Hepatocytes show robust LC3 expression
• Skeletal muscle: Particularly in type I (slow-twitch) fibers
• Heart: Cardiomyocytes require LC3 for mitochondrial quality control
• Kidney: Tubular epithelial cells
• Pancreas: Islet cells

Protein Structure and Biochemistry

Domain Architecture

MAP1LC3A contains several functional regions:

• Contains the β-grasp fold characteristic of ubiquitin-like proteins
• Critical glycine residue (Gly120) at the C-terminus for lipidation

• Comprises the majority of the protein sequence
• Maintains structural integrity necessary for function

• Contains the PE-conjugation site
• Protected by the propeptide until processing

Post-Translational Modifications

MAP1LC3A undergoes critical modifications essential for its function:

• Atg4B is the primary protease in mammals
• This step is reversible under certain conditions

• Atg7 serves as the E1 enzyme
• Atg3 serves as the E2 enzyme
• LC3-II is the form that associates with autophagosomal membranes

• Ser3 phosphorylation by PKA inhibits LC3 function
• mTOR phosphorylates LC3 to regulate autophagosome formation

Structural Features

• Ubiquitin-like fold: The N-terminal region adopts a ubiquitin-like β-grasp fold, enabling interactions with autophagy receptors
• Hydrophobic patch: Critical for membrane interaction and insertion
• C-terminal glycine: Essential for PE conjugation, exposed after Atg4 cleavage
• Dimerization interface: LC3 can form dimers, which may regulate its function

The Autophagy Pathway

Overview of Macroautophagy

Autophagy is a fundamental cellular process for degrading and recycling cytoplasmic components. The formation of autophagosomes involves several sequential steps:

• Nutrient deprivation or stress activates AMPK
• Inactivation of mTORC1 releases inhibition on ULK1/2

• Beclin 1 is the core component
• Vps34 is the catalytic subunit generating PI3P

• Atg12-Atg5 conjugate system
• LC3 lipidation system
• Membrane sources include ER, Golgi, and plasma membrane

• Critical step for cargo sequestration
• Closure is mediated by SNARE proteins

• Requires LAMP proteins and SNAREs
• Acidification activates lysosomal enzymes

LC3 in Autophagosome Formation

LC3 plays multiple critical roles in autophagosome biogenesis:

• LC3-II is inserted into both inner and outer membranes
• The outer membrane LC3 is removed before lysosomal fusion

• The LIR (LC3-interacting region) motif is essential
• Multiple receptors can link diverse cargo types

• LC3 interacts with fusion machinery proteins
• Helps ensure proper membrane tethering

• LC3 is removed from the outer membrane prior to fusion
• This step determines autophagic flux efficiency

Types of Autophagy

MAP1LC3A in Neurodegenerative Diseases

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), autophagy is profoundly dysregulated, and MAP1LC3A plays complex roles:

• Autophagosomes accumulate in dystrophic neurites
• This reflects either increased formation or decreased clearance

• Aβ can be degraded by autophagy
• However, plaque-associated autophagy is often inefficient

• Tau pathology impairs LC3 transport along microtubules
• This creates a vicious cycle of impaired autophagy and tau accumulation

• Rapamycin treatment reduces Aβ accumulation
• Autophagy induction improves cognitive function in mouse models

• ER stress triggers autophagy that is compromised in AD
• This contributes to protein misfolding and aggregation

• Impaired autophagy contributes to synaptic loss in AD
• LC3 dysfunction affects presynaptic terminal maintenance

Parkinson's Disease

MAP1LC3A is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease) due to its role in clearing protein aggregates and damaged mitochondria:

• p62-mediated selective autophagy targets SNCA
• Impaired autophagy leads to Lewy body formation

• Parkin ubiquitinates mitochondrial proteins
• p62 recruits LC3 to damaged mitochondria for mitophagy

• Variants affecting autophagy efficiency
• May modify age of onset or disease severity

• Mitochondrial stress requires mitophagy
• Protein quality control is essential for neuronal survival

• LRRK2 can phosphorylate autophagy proteins
• PD-associated mutations disrupt normal autophagy

• GCase deficiency leads to autophagic impairment
• Contributes to α-synuclein accumulation

Amyotrophic Lateral Sclerosis (ALS)

• Mutant proteins form aggregates that overwhelm autophagy
• Enhancing autophagy can reduce aggregate load

• This reflects either increased autophagosome formation or blocked fusion
• The exact mechanism remains under investigation

• Transport deficits impair autophagy in distal axons
• Contributes to "dying-back" pattern of axonal loss

• C9orf72 regulates lysosomal function
• Loss of function impairs autophagy

Huntington's Disease

• Mutant Htt forms aggregates that require autophagy for clearance
• Enhancing autophagy reduces aggregation and toxicity

• Rapamycin and trehalose show promise in models
• Early intervention appears most effective

• Transcription factor dysfunction affects LC3 levels
• Contributes to reduced autophagy capacity

Other Neurodegenerative Conditions

Autophagy in Neuronal Physiology

Synaptic Function

MAP1LC3A plays essential roles in neuronal function beyond general autophagy:

• Autophagy at synapses regulates vesicle pool size
• Required for sustained synaptic transmission

• Activity-dependent autophagy modulates release probability
• Regulates presynaptic protein turnover

• Autophagy regulates synaptic plasticity
• Controls receptor density at the synapse

• Critical for neural circuit refinement
• Implicated in neurodevelopmental disorders

Axonal Transport

LC3 localizes to axonal autophagosomes that are transported bidirectionally:

• Anterograde transport: Moves autophagosomes from cell body to distal axons via kinesin motors
• Retrograde transport: Returns cargo for degradation in the soma via dynein motors
• Regulatory proteins: Kinesin-1 and dynein-dynactin complex mediate this transport
• Pathology: Disrupted transport contributes to neurodegeneration

Dendritic Branching

Autophagy, mediated by LC3, regulates dendritic arborization:

• Selective degradation of cytoskeletal proteins shapes dendritic morphology
• Activity-dependent autophagy modulates synaptic plasticity
• autophagy regulates dendritic spine formation and maintenance

Neuronal Survival

Autophagy serves as a critical survival mechanism in neurons:

• Protects against proteotoxic stress
• Maintains mitochondrial health through mitophagy
• Prevents apoptosis under stress conditions

Therapeutic Targeting

Autophagy Inducers

• Activate ULK1/2 complex by relieving mTORC1 inhibition
• Widely used in research and clinical settings

• Activate ULK1/2 directly
• Also improve metabolic health

• Often work through multiple mechanisms
• Generally have better safety profiles

Autophagy Modulators in Clinical Trials

Challenges

Interaction Network

MAP1LC3A interacts with multiple proteins:

Genetic Aspects

Polymorphisms

Several MAP1LC3A polymorphisms have been studied:

• rs9370149: Associated with PD risk in Asian populations
• rs2293889: May affect autophagy efficiency
• Promoter variants: Influence expression levels

Mutations

While rare, mutations in autophagy genes including MAP1LC3A are associated with:

• Neurodegeneration susceptibility
• Congenital disorders
• Cancer (in some contexts)

Animal Models

Knockout Studies

• Map1lc3a knockout mice: Viable but show increased sensitivity to stressors
• Conditional knockout: Brain-specific knockouts reveal neurological phenotypes
• Phenotypes include: Enhanced protein aggregation, mitochondrial dysfunction

Transgenic Models

• GFP-LC3 transgenic mice: Enable visualization of autophagic flux in vivo
• mCherry-GFP-LC3: Used for measuring autophagosome-lysosome fusion
• LC3-CRISPR models: Genetic manipulation of LC3 expression

Disease Models

• α-synuclein transgenic mice: Used to study aggrephagy
• PINK1/Parkin knockout mice: Mitophagy studies
• SOD1 mutant mice: ALS models

Biomarkers

LC3 as a Biomarker

Clinical Applications

• Cerebrospinal fluid LC3 levels as a biomarker for neurodegeneration
• PET tracers for autophagosome visualization (under development)
• Blood-based LC3 measurements for disease monitoring

Cross-Linking to Other Neurodegeneration Pathways

Mitochondrial Quality Control

LC3-mediated mitophagy is essential for neuronal health:

• PINK1-Parkin pathway recruits LC3 to damaged mitochondria
• Mutations in [PINK1](/genes/pink1) and [parkin](/genes/parkin) impair mitophagy
• Dopaminergic neurons are particularly dependent on mitophagy
• Impaired mitophagy leads to neuronal death in PD models

Neuroinflammation

Autophagy intersects with inflammatory pathways:

• LC3 deficiency leads to inflammasome activation
• Microglial autophagy regulates cytokine production
• Cross-talk between autophagy and NF-κB signaling
• Therapeutic modulation affects inflammatory responses

Protein Quality Control

The ubiquitin-proteasome system and autophagy work together:

• p62 bridges ubiquitinated proteins to LC3
• Aggresomes are cleared by LC3-mediated autophagy
• Impairment leads to protein aggregate accumulation
• Both systems are impaired in neurodegeneration

Connections to Specific Neurodegeneration Proteins

LC3 Family Members

The MAP1LC3 family includes several related proteins:

These family members have overlapping but distinct functions in autophagy.

Comparative Biology

The autophagy pathway shows conservation across eukaryotes:

• Yeast: Atg8 is the LC3 ortholog
• Drosophila: Drosophila has a single Atg8 homolog
• Zebrafish: Multiple LC3 isoforms with distinct expression patterns
• Mice: Multiple isoforms similar to humans
• Conservation: Core autophagy machinery is highly conserved

Future Directions

Emerging Research Areas

Unresolved Questions

LC3 in Aging and Normal Brain Function

Brain Aging

Autophagy declines with age, contributing to cognitive decline:

• LC3 lipidation decreases in aged neurons
• Autophagosome transport becomes impaired
• Protein aggregate accumulation increases

Circadian Regulation

Autophagy exhibits circadian rhythms in the brain:

• LC3 expression peaks during sleep
• Sleep deprivation impairs autophagy
• This may explain the restorative function of sleep

Summary

MAP1LC3A is a fundamental protein in the autophagy pathway, essential for neuronal protein quality control and mitochondrial maintenance. In neurodegenerative diseases, autophagy dysfunction contributes to the accumulation of protein aggregates and damaged organelles. The protein plays roles in synaptic function, axonal transport, and dendritic morphology. Therapeutic modulation of LC3-mediated autophagy remains a promising approach for treating AD, PD, and related conditions.

See Also

• [SNCA Protein](/proteins/gabarap-protein)
• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Parkinson's disease](/diseases/parkinsons-disease)

External Links

• [NCBI Gene: SNCA](https://www.ncbi.nlm.nih.gov/gene/?term=SNCA)
• [GeneCards: SNCA](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SNCA)
• [OMIM: SNCA](https://omim.org/search?search=SNCA)
• [Ensembl: SNCA](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=SNCA)
• [Allen Brain Atlas: SNCA](https://human.brain-map.org/microarray/search/show?search_term=SNCA)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving MAP1LC3A Gene discovered through SciDEX knowledge graph analysis: